TriSalus Life Sciences (NASDAQ:TLSI) Price Target Cut to $11.00 by Analysts at Canaccord Genuity Group

TriSalus Life Sciences (NASDAQ:TLSI) had its price target dropped by investment analysts at Canaccord Genuity Group from $12.00 to $11.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price points to a potential upside of 179.90% from the stock’s previous close.

TLSI has been the subject of a number of other reports. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price for the company. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 price objective for the company. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Stock Down 2.0 %

TLSI stock opened at $3.93 on Friday. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42. The firm’s fifty day simple moving average is $4.33 and its two-hundred day simple moving average is $5.78. The stock has a market capitalization of $119.83 million, a price-to-earnings ratio of -1.58 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $7.36 million during the quarter. As a group, equities research analysts expect that TriSalus Life Sciences will post -1.5 EPS for the current year.

Insider Buying and Selling at TriSalus Life Sciences

In other news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the purchase, the chief executive officer now directly owns 377,382 shares in the company, valued at approximately $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 32.80% of the stock is owned by insiders.

Institutional Trading of TriSalus Life Sciences

A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the 3rd quarter worth approximately $108,000. MSD Partners L.P. acquired a new position in TriSalus Life Sciences during the 3rd quarter valued at approximately $184,000. Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the 3rd quarter valued at approximately $66,000. Finally, Duquesne Family Office LLC raised its stake in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.